Kalvista Pharmaceuticals (Ireland) Ltd

KalVista Pharmaceuticals (Ireland) Limited is a science‑driven biopharmaceutical company dedicated to improving everyday life for people living with hereditary angioedema (HAE). By harnessing orally‑delivered small‑molecule medicines, KalVista is reshaping the treatment landscape and offering patients a new, convenient option beyond the limitations of existing injectable therapies.

The company’s flagship product, EKTERLY® (sebetralstat), is the first and only oral treatment for HAE and has already secured approval in Japan, marking a significant milestone for the organisation. KalVista’s pipeline continues to focus on innovative medicines that address unmet needs, with a clear commitment to advancing science and elevating the standard of care for a broader range of diseases.

Rooted in Ireland, KalVista brings together a talented team of professionals and experienced scientists who share a common purpose: to empower patients to engage fully in everyday life, free from the constraints of their condition. Their collaborative, patient‑centred approach makes them a leading voice in the evolving field of rare‑disease therapeutics.